Serodus ASA (SER)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Serodus ASA (SER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013362
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Serodus ASA (Serodus) is a drug development company that focuses on the development of products for unmet medical needs in areas such as diabetes and diabetic comorbidities. The company’s pipeline products include SER150DN, an anti-inflammatory compound under development for diabetic nephropathy; SER130AMI, an interleukin-4 agonist for acute myocardial infarction; SER100PH, for group I or IV pulmonary hypertension; and SER100TRISH, an opioid receptor like-1 (ORL-1, nociceptin) receptor partial agonist, for therapy resistant isolated systolic hypertension, besides SER140T2D, an interleukin-1 receptor antagonist in preclinical phase for Type 2 Diabetes. It enters into licensing arrangements and collaborates with biotech companies and universities to develop its product pipeline. Serodus is headquartered in Oslo, Norway.

Serodus ASA (SER) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Serodus ASA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Serodus ASA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Serodus ASA, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Serodus Raises US$0.09 Million In Venture Financing 10
Licensing Agreements 11
Evolva And Serodus Enter Into Licensing Agreement For EV-077 11
Equity Offering 12
Serodus Raises USD1.2 Million in Private Placement of Shares 12
Serodus to Raise up to USD3.7 Million in Rights Offering of Shares 13
Serodus Completes Public Offering of Shares for USD1.71 Million 14
Serodus Completes Private Placement Of Shares For US$4.9 Million 15
Serodus Completes IPO Of US$0.7 Million 16
Acquisition 18
Viggo Harboe Holding 2006 to Acquire Additional 8.1% Stake in Serodus 18
Serodus Completes Acquisition of Phlogo for USD0.9 Million 19
Serodus ASA – Key Competitors 20
Serodus ASA – Key Employees 21
Serodus ASA – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Feb 27, 2017: Serodus: Results for Q4-2016 23
Oct 27, 2016: Serodus: Results Q3 2016 24
Aug 18, 2016: Serodus Reports Q2-2016 Interim Results 29
Apr 27, 2016: Serodus : Q1-2016 Interim results 31
Feb 17, 2016: Serodus: Q4-2015 Interim results 32
Corporate Communications 33
Jun 27, 2016: Serodus: Changes in the Board of Directors 33
Clinical Trials 34
Feb 03, 2016: Serodus announces completion of patient enrollment of the first cohort in Phase 2a clinical trial of SER150 in patients with Diabetic Nephropathy 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Serodus ASA, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Serodus ASA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Serodus ASA, Deals By Therapy Area, 2011 to YTD 2017 8
Serodus ASA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Serodus Raises US$0.09 Million In Venture Financing 10
Evolva And Serodus Enter Into Licensing Agreement For EV-077 11
Serodus Raises USD1.2 Million in Private Placement of Shares 12
Serodus to Raise up to USD3.7 Million in Rights Offering of Shares 13
Serodus Completes Public Offering of Shares for USD1.71 Million 14
Serodus Completes Private Placement Of Shares For US$4.9 Million 15
Serodus Completes IPO Of US$0.7 Million 16
Viggo Harboe Holding 2006 to Acquire Additional 8.1% Stake in Serodus 18
Serodus Completes Acquisition of Phlogo for USD0.9 Million 19
Serodus ASA, Key Competitors 20
Serodus ASA, Key Employees 21
Serodus ASA, Subsidiaries 22

★調査レポート[Serodus ASA (SER)-製薬・医療分野:企業M&A・提携分析] (コード:DATA8013362)販売に関する免責事項を必ずご確認ください。
★調査レポート[Serodus ASA (SER)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆